Physician profile
John R Rowe
NPI 1508815069
$4,576.88
in general payments reported to CMS, 2019-2025
43 companies · $421 in 2025
The $421 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $737 · 2020: $700 · 2021: $734 · 2022: $685 · 2023: $550 · 2024: $749 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,720.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $460.80 | 2019-2025 | |
| Novo Nordisk INC | $375.50 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $364.58 | 2021-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $361.44 | 2019-2025 | Fasenra, Farxiga |
| Amgen INC. | $348.88 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $319.88 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $297.14 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.99 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $208.44 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $193.15 | 2019-2021 | |
| Lilly USA, LLC | $152.18 | 2019-2024 | Jardiance, Mounjaro |
| Abbott Laboratories | $142.10 | 2021-2025 | Eterna |
| Merck Sharp & Dohme LLC | $138.51 | 2019-2021 | |
| Eisai INC. | $92.20 | 2020-2024 | |
| Amarin Pharma, INC. | $89.96 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.